Primary Thrombotic Microangiopathy in Pediatric Patients

Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology . A retrospective study that included patients younger than 18 years diagnose...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Global Pediatric Health
Online Access:https://doi.org/10.1177/2333794X241307535
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850114780285632512
author Andrés David Aranzazu Ceballos MD
Lina María Martínez Sánchez MSc
Ana Paulina Pamplona Sierra MD
Daniela Vergara Yánez MD
Liliana Franco Hincapié PhD
Richard Baquero Rodriguez MD
author_facet Andrés David Aranzazu Ceballos MD
Lina María Martínez Sánchez MSc
Ana Paulina Pamplona Sierra MD
Daniela Vergara Yánez MD
Liliana Franco Hincapié PhD
Richard Baquero Rodriguez MD
author_sort Andrés David Aranzazu Ceballos MD
collection DOAJ
description Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology . A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results . Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion . This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.
format Article
id doaj-art-e036b4bca445491a9df0dbb6f8ecabd3
institution OA Journals
issn 2333-794X
language English
publishDate 2024-12-01
publisher SAGE Publishing
record_format Article
series Global Pediatric Health
spelling doaj-art-e036b4bca445491a9df0dbb6f8ecabd32025-08-20T02:36:45ZengSAGE PublishingGlobal Pediatric Health2333-794X2024-12-011110.1177/2333794X241307535Primary Thrombotic Microangiopathy in Pediatric PatientsAndrés David Aranzazu Ceballos MD0Lina María Martínez Sánchez MSc1Ana Paulina Pamplona Sierra MD2Daniela Vergara Yánez MD3Liliana Franco Hincapié PhD4Richard Baquero Rodriguez MD5Universidad Pontificia Bolivariana, Medellín, ColombiaUniversidad Pontificia Bolivariana, Medellín, ColombiaHospital Pablo Tobón Uribe, Medellín, ColombiaUniversidad Pontificia Bolivariana, Medellín, ColombiaUniversidad Pontificia Bolivariana, Medellín, ColombiaHospital Universitario San Vicente Fundacion, Antioquia, ColombiaBackground . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology . A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results . Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion . This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.https://doi.org/10.1177/2333794X241307535
spellingShingle Andrés David Aranzazu Ceballos MD
Lina María Martínez Sánchez MSc
Ana Paulina Pamplona Sierra MD
Daniela Vergara Yánez MD
Liliana Franco Hincapié PhD
Richard Baquero Rodriguez MD
Primary Thrombotic Microangiopathy in Pediatric Patients
Global Pediatric Health
title Primary Thrombotic Microangiopathy in Pediatric Patients
title_full Primary Thrombotic Microangiopathy in Pediatric Patients
title_fullStr Primary Thrombotic Microangiopathy in Pediatric Patients
title_full_unstemmed Primary Thrombotic Microangiopathy in Pediatric Patients
title_short Primary Thrombotic Microangiopathy in Pediatric Patients
title_sort primary thrombotic microangiopathy in pediatric patients
url https://doi.org/10.1177/2333794X241307535
work_keys_str_mv AT andresdavidaranzazuceballosmd primarythromboticmicroangiopathyinpediatricpatients
AT linamariamartinezsanchezmsc primarythromboticmicroangiopathyinpediatricpatients
AT anapaulinapamplonasierramd primarythromboticmicroangiopathyinpediatricpatients
AT danielavergarayanezmd primarythromboticmicroangiopathyinpediatricpatients
AT lilianafrancohincapiephd primarythromboticmicroangiopathyinpediatricpatients
AT richardbaquerorodriguezmd primarythromboticmicroangiopathyinpediatricpatients